Merck touts latest results for antibiotic Recarbrio by Eric Sagonowsky Tuesday, October 1, 2019 Merck's antibiotic Recarbrio won its first FDA nod in July. Now, thanks to new trial results in severe pneumonia, it's eyeing another approval.
Merck wins nod for Recarbrio, a resistance-fighting combo drug by Eric Sagonowsky Wednesday, July 17, 2019 On the heels of its Zerbaxa label expansion last month, Merck scored an FDA nod for an entirely new antibacterial drug combo called Recarbrio.
Merck scores new Zerbaxa use years after Cubist buyout by Eric Sagonowsky Monday, June 3, 2019 Merck won a label expansion for Zerbaxa, an antibiotic the company picked up in its 2014 buyout of Cubist Pharmaceuticals.
